Novo, Eli Lilly to dominate global pharma sales in 2025: report

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers’ (BMY) cancer medication Opdivo from the 10-product list.

The GLP-1s semaglutide and